IP Library › Granted Patent US 12686712
Granted Patent B2
US 12686712 · App. 17/796,661 · Granted Jul 21, 2026

Antibody, related use, pharmaceutical composition including method for diagnosing fungal infections, fungal infection diagnosis kit and method for treating fungal infections

Inventors: Alexandre Bezerra Conde Figueiredo (Rio de Janeiro, BR); Marcio Lourenco Rodrigues (Curitiba, BR); Fernando de Paiva Conte (Rio de Janeiro, BR); Fernanda Lopes Fonseca (Rio de Janeiro, BR); Marcia Arissawa (Niterói, BR)
Assignee: FUNDAÇÃO OSWALDO CRUZ
C07K16/14C07K2317/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12686712
App. No.
17/796,661
Granted
Jul 21, 2026
Kind
B2
Abstract

Present invention provides monoclonal antibody against chitin oligomer through hybridoma technique. Antibodies abovementioned can be used as tools to fungal infection diagnostic and treatment. Pharmaceutical compositions and fungal infection treatment kits are also disclosed, including antibodies abovementioned. Moreover, fungal infection diagnostic method is also disclosed, using antibodies abovementioned and their use in drug preparation to treat fungal infections.

Claims (18)

1 . An isolated monoclonal antibody that specifically binds to a fungal chitooligomer, comprising:

(i) a heavy chain variable region comprising a CDR1 sequence as set forth in SEO ID NO: 1, a CDR2 sequence as set forth in SEQ ID NO: 2, and a CDR3 sequence as set forth in SEQ ID NO: 3; and

(ii) a light chain variable region comprising a CDR1 sequence as set forth in SEQ ID NO: 4, a CDR2 sequence as set forth in SEQ ID NO: 5, and a CDR3 sequence as set forth in SEQ ID NO: 6;

or

(i) a heavy chain variable region comprising a CDR1 sequence as set forth in SEQ ID NO: 7, a CDR2 sequence as set forth in SEQ ID NO: 8, and a CDR3 sequence as set forth in SEQ ID NO: 9; and

(ii) a light chain variable region comprising a CDR1 sequence as set forth in SEQ ID NO: 10, a CDR2 sequence as set forth in SEQ ID NO: 11, and a CDR3 sequence as set forth in SEQ ID NO: 12.

2 . The antibody according to claim 1 , wherein the antibody is selected from the group consisting of a murine antibody, humanized antibody, a human antibody, and a chimeric antibody.

3 . A pharmaceutical composition, comprising the antibody of claim 1 and a pharmaceutically acceptable carrier, and optionally an excipient.

4 . The pharmaceutical composition according to claim 3 , further comprising polyenes and/or azoles.

5 . The pharmaceutical composition according to claim 4 , further comprising AmB and/or FLC.

6 . A method for diagnosing a fungal infection, comprising:

(i) providing the antibody of claim 1 with a sample obtained from a patient,

(ii) contacting said antibody with a biological sample to be tested under conditions and duration sufficient to develop an antigenic/antibody complex; and

(iii) detecting said antigenic/antibody complex using a detection technique capable of generating detectable signal corresponding to said antigenic/antibody complex.

7 . The method according to claim 6 , wherein said biological sample is selected from the group consisting of saliva, urine, serum, blood, bronchoalveolar lavage, peritoneal fluid or liquid, and any other biological fluids of a patient.

8 . A fungal infection diagnostic kit, comprising the antibody of claim 1 .

9 . The diagnostic kit according to claim 8 , further comprising instructions for usage.

10 . The diagnostic kit according to claim 8 , further comprising a detection medium configured to generate a detectable signal corresponding to an antigen-antibody complex.